Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review

Abstract EN

Even with substantial advances in cardiovascular therapy, the morbidity and mortality rates of diabetic cardiomyopathy (DCM) continually increase.

Hence, a feasible therapeutic approach is urgently needed.

Objectives.

This work is aimed at systemically reviewing literature and addressing cell targets in DCM through the possible cardioprotection of G.

lucidum through its antioxidant effects by using the Open Targets Platform (OTP) website.

Methods.

The OTP website version of 19.11 was accessed in December 2019 to identify the studies in DCM involving G.

lucidum.

Results.

Among the 157 cell targets associated with DCM, the mammalian target of rapamycin (mTOR) was shared by all evidence, drug, and text mining data with 0.08 score association.

mTOR also had the highest score association 0.1 with autophagy in DCM.

Among the 1731 studies of indexed PubMed articles on G.

lucidum published between 1985 and 2019, 33 addressed the antioxidant effects of G.

lucidum and its molecular signal pathways involving oxidative stress and therefore were included in the current work.

Conclusion.

mTOR is one of the targets by DCM and can be inhibited by the antioxidative properties of G.

lucidum directly via scavenging radicals and indirectly via modulating mTOR signal pathways such as Wnt signaling pathway, Erk1/2 signaling, and NF-κB pathways.